


RESEARCH ARTICLE

Open Access



CT differentiation of gastric ectopic pancreas from gastric stromal tumor

Chang Liu¹, Fang Yang², Wenming Zhang³, Weiqun Ao⁴, Yongyu An⁴, Cui Zhang⁴, Bailing Dai⁴, Cailing Pu³ and Jian Wang^{4*} 

Abstract

Background: Gastric ectopic pancreas (GEPs) is a rare developmental anomaly which is difficult to differentiate it from submucosal tumor such as gastric stromal tumor (GST) by imaging methods. Since the treatments of the GEPs and GST are totally different, a correct diagnosis is essential. Therefore, we retrospectively investigated the CT features of them to help us deepen the understanding of GEPs and GST.

Methods: This study enrolled 17 GEPs and 119 GST, which were proven pathologically. We assessed clinical and CT features to identify significant differential features of GEPs from GST using univariate and multivariate analyses.

Results: In univariate analysis, among all clinicoradiologic features, features of age, symptom, tumor marker, location, contour, peritumoral infiltration or fat-line of peritumor, necrosis, calcification, CT attenuation value of unenhancement phase/arterial phase/portal venous phase (CTu/CTa/CTp), the CT attenuation value of arterial phase/portal venous phase minus that of unenhanced phase (DEAP/DEPP), long diameter (LD), short diameter (SD) were considered statistically significant for the differentiation of them. And the multivariate analysis revealed that location, peritumoral infiltration or fat-line of peritumor, necrosis and DEPP were independent factors affecting the identification of them. In addition, ROC analysis showed that the test efficiency of CTp was perfect (AUC = 0.900).

Conclusion: Location, the presence of peritumoral infiltration or fat-line of peritumor, necrosis and DEPP are useful CT differentiators of GEPs from GST. In addition, the test efficiency of CTp in differentiating them was perfect (AUC = 0.900).

Keywords: Gastric ectopic pancreas, Gastric stromal tumor, Subepithelial tumors, Gastric neoplasm, Computed tomography

Background

Ectopic pancreas, which was first described by Klob in 1859, is a rare developmental anomaly that is defined as pancreatic tissue lacking anatomic or vascular continuity with the main body of the gland [1–3]. It can occur anywhere along distal end of the esophagus to the colon, and of the gastrointestinal lesions, stomach (30%) is the most common area, followed by duodenum (25%) and jejunum

(15%) [3]. Ectopic pancreas is usually discovered incidentally during surgery or autopsy and is generally asymptomatic. However, some patients with ectopic pancreas may have clinical symptoms such as abdominal pain, gastrointestinal bleeding, and obstruction when complicated with pancreatitis, pseudocyst, insulinoma, and pancreatic cancer [2, 4–7].

Although there were many diagnostic imaging methods such as computed tomography (CT), ultrasonography and endoscopic ultrasonography, the diagnosis of ectopic pancreas was difficult due to its non-specific imaging characteristics. Ectopic pancreas may commonly present

*Correspondence: 119202405@qq.com

⁴ Department of Radiology, TongDe Hospital of Zhejiang Province, No. 234, Gucui Road, Hangzhou 310012, Zhejiang Province, China
Full list of author information is available at the end of the article



as a submucosal mass in gastrointestinal tract [8] and were easily misdiagnosed with other submucosal tumor such as gastric stromal tumor (GST) and leiomyoma. As we know, GST is the most common subepithelial lesion and accounts for 90% of gastric submucosal tumors [8, 9]. Additionally, the standard treatment for a GST without metastasis is surgical resection and a GST with metastasis is usually treated by tyrosine inhibitors such as imatinib. However, an ectopic pancreas would not need clinical treatment unless it is symptomatic, in addition, whether to remove suspected ectopic pancreas that is found incidentally is still a controversial issue [10]. So it is of great clinical significance to identify ectopic pancreas and gastrointestinal stromal tumors on image.

As we know, CT is the most commonly used noninvasive modality for preoperative evaluation of gastric tumors due to its well-standardized protocol and easy accessibility. However, CT features of gastric ectopic pancreas (GEPs) as well as differential imaging features of GEPs from GST have not yet been investigated completely. Therefore, our study retrospectively investigates the differential CT features of GEPs from GST.

Methods

Patients

Our retrospective study was approved by the ethics committee of Tongde hospital of Zhejiang Province and Sir Run Run Shaw Hospital, Zhejiang University School of Medicine³ and did not require informed consent. All procedures performed in studies involving human participants were in compliance with the 1964 Helsinki Declaration and its later amendments.

We queried pathology database of our institute to derive all histologically proved cases of GEPs from January 2007 to June 2019 and GST from January 2016 to June 2019. All patients were histologically proven by surgical resection. Finally total 19 cases of GEPs and 147 cases of GST were identified in this query. We included patients who satisfied the following inclusion criteria: (1) patients who had preoperative CT images with optimal gastric distension, (2) patients who had integrated clinical date, (3) the lesion was solitary, (4) the maximum diameter of the tumor was no less than 10 mm. Finally, 17 patients with histopathologically proven GEPs and 119 patients with GST comprised our study population (Fig. 1).

Clinical features


The clinical features of all patients were analyzed by one author (C.L.) using the medical records of hospital. For each patient, the gender, age, the presence of clinical manifestations and the level of tumor marker (ferritin) were analysed.

CT image acquisition

All Enhanced CT images were obtained from multidetector CT scanners (SOMATOM, Sensation 16, Siemens, Forchheim, Germany and SOMATOM, Definition AS+, Siemens, Forchheim, Germany). All patients drank 600–800 ml of water before CT examination. The CT scan parameters were set as follows: for SOMATOM Sensation 16, beam collimation = 1.2 mm × 16, pitch = 1, kVp/effective mA = 120/300, rotation time = 0.5 s and reconstruction section thickness = 5 mm; for SOMATOM, Definition AS+, beam collimation = 1.2 mm × 32, pitch = 1, kVp/effective mA = 120/160, rotation time = 0.5 s, and reconstruction section thickness = 5 mm. Patients were injected with non-ionic contrast material (Ultravist; 300 mg I/ml, Bayer Schering Pharma AG, Berlin, Germany or Iopamidol; 300 mg I/ml, Bracco Sine Pharma AG, Shanghai, China) with antecubital venous access at a rate of 3.0 ml/sec and a total of 90–120 ml (1.5 mL per kilogram of body weight) was injected by using the CT-compatible power injector during arterial and parenchymal phase. The scanning delay for arterial imaging was determined by using automated scan-triggering software Arterial scanning automatically began 7.0 s after the trigger attenuation threshold (100 HU) was reached at the level of the superior abdominal aorta and parenchymal scanning began at a delay of 45 s after arterial scanning.

Imaging analysis

All CT images were respectively interpreted by two radiologists (C.L. and J.W.) who had 4-yr (C.L.) and 12-yr (J.W.). Both radiologists were aware that the study population had either GEPs or GST, but were blinded to their histological subtypes. The following CT features of the primary gastric lesion were assessed: (1) the long diameter (LD) and short diameter (SD), (2) the ratio of Long diameter to short diameter (LD/SD), (3) location of the lesion (cardia; fundus; body; antrum), (4) contour of the lesion (round; oval; irregular), (5) Growth pattern (endophytic; exophytic; mixed), (6) the presence of peritumoral infiltration or fat-line of peritumor, wherein, the peritumoral infiltration was defined as a dense band-like perigastric fat infiltration; the fat-line of peritumor was defined as a fat space between the tumor and serosal layer, (7) the presence of necrosis, wherein, the necrosis was defined as the presence of non-enhancement low-density area within the tumor, (8) the presence of calcification, (9) the presence of surface ulceration, (10) the presence of lymph node, wherein, the lymph node was defined as the shortest axis length of the largest lymph node was more than 10 mm, (11) the CT attenuation value of unenhancement phase (CT_u), (12) arterial enhancement (CT_a) of the tumor, which measured



the CT value at a represent region of interest (ROI), (13) parenchymal enhancement (CTp), (14) the CT attenuation value of arterial phase minus unenhancement phase (DEAP), (15) the CT attenuation value of portal venous phase minus unenhancement phase (DEPP).

Statistical analysis

All statistical analyses were performed using commercial software, SPSS 22.0 for Windows (SPSS Inc, Chicago, IL,

USA). The prevalence of clinical and CT features were compared using Student’s t-test and χ^2 test, and binary logistic regression analyses were performed to achieve the most significant differential CT features. Receiver operating characteristic curve (ROC) analysis was performed to ascertain the optimal cut-off value of significant quantitative CT features, such as LD, SD, CTu, CTa, CTp, DEAP, DEPP and to obtain the value of sensitivity and specificity of qualitative CT features, such

Table 1 Clinical characteristics of 136 patients with GEPs and GST

| Clinical characteristics | GEPs (n = 17) | GST (n = 119) | P value |
|-----------------------------|-----------------------|-----------------------|-------------------|
| Gender | | | 0.948 |
| Male | 7 (41.2) | 50 (26.3) | |
| Female | 10 (58.8) | 69 (73.7) | |
| Mean age (years, age range) | 38.53 ± 2.468 (24–58) | 59.46 ± 10.78 (29–88) | < 0.001 |
| Symptom | | | 0.001 |
| Yes | 3 (21.4) | 70 (58.8) | |
| No | 14 (78.6) | 49 (41.2) | |
| Tumor marker ^a | | | 0.013 |
| Abnormal | 1 (5.9) | 43 (36.1) | |
| Normal | 16 (94.1) | 76 (63.9) | |

P values written in bold indicate a significant difference between the tumors

GEPs gastric ectopic pancreas, GST gastrointestinal stromal tumor

^a Abnormal ferritin level (excluding abnormal CA125 in the two GST)

as location, contour, the presence of serosal invasion or fat-line of peritumor, necrosis and calcification. A *P* value < 0.05 was considered statistically significance.

Result

Clinical features

The clinical characteristics of GEPs and GST patients were summarized in Table 1. There was no significant difference in gender distribution between the two groups. However, there were significant differences in mean age, symptom and the level of serum tumor marker (*P* < 0.05).

Qualitative and quantitative image analysis

Results of the qualitative and quantitative images analysis were presented in Table 2. The location of tumor was significantly different between the two groups (*P* < 0.05)—Or rather, there was a significant difference in the distribution of tumors in gastric fundus between two groups (*P* < 0.05). The majority of GEPs were located in body (64.7% [11/17]) and none (0% [0/17]) of GEPs were located in gastric fundus, whereas the majority of GST were located in body (47.1% [56/119]) and fundus (34.4% [41/119]). In addition, the contour of GEPs tended to be oval (58.8% [10/17]), while the contour of GST were round (30.3% [36/119]) or oval (30.3% [36/119]). Furthermore, GST were more likely to have the presence of peritumoral infiltration or fat-line of peritumor (*P* < 0.05). Moreover, there were significant differences in the necrosis, calcification, surface ulceration, lymph node. Although there wasn't any significant difference about the tumor growth pattern, the GST were tended to grow exophytically.

When it comes to quantitative CT images analysis, the CT attenuation values such as CTu, CTa, CTp, DEAP, DEPP of GEPs were significantly higher

(40.55HU ± 8.673 for CTu, 71.35HU ± 19.49 for CTa, 95.09HU ± 13.15 for CTp, 37.44 HU ± 15.70 for DEAP and 54.49HU ± 17.69 for DEPP) than that of GST (34.24HU ± 7.19 for CTu, 54.57HU ± 13.77 for CTa, 68.92HU ± 17.87 for CTp, 20.37HU ± 11.81 for DEAP and 34.26HU ± 15.57 for DEPP) (*P* < 0.05). Moreover, the LD and SD were also the significant CT features in differentiating GEPs from GST (*P* < 0.05). In addition, multivariate analysis revealed that location, the presence of peritumoral infiltration or fat-line of peritumor (Figs. 2, 3), necrosis and DEPP were independent factors affecting the identification of GEPs and GST.

Sensitivity and specificity values for CT diagnosis

Table 3 showed the sensitivity and specificity values of each significant CT feature for differentiating GEPs from GST. According to the ROC analysis (Fig. 4), the largest area under the curve (AUC) was the CTp (0.900), followed by the DEPP (0.832), the CTa (0.821), the DEAP (0.806), the SD (0.757), the CTu (0.727) and the LD (0.726), which were significantly continuous variables differentiated GEPs from GST. Using clustered boxplot to study the significant continuous variables—CT attenuation value and diameter for differentiating GEPs from GST, we found the CT median attenuation value was universally higher for the GEPs than that of the GST, no matter what CTu, CTa, CTp, DEAP or DEPP, while the diameter was universally smaller, no matter LD or SD (Fig. 5).

Table 2 CT findings of 136 patients with GEPs and GST

| CT features | GEPs (n = 17) | GST (n = 119) | P value | |
|---------------------------------------------------|---------------|---------------|------------------------------|--------------|
| | | | Univariate | Multivariate |
| Qualitative analysis | | | | |
| Location | | | 0.006 | 0.021 |
| Cardia | 1 (5.9%) | 9(7.6%) | 1.000 | |
| Fundus | 0 (0%) | 41 (34.4%) | 0.004 | |
| Body | 11 (64.7%) | 56(47.1%) | 0.173 | |
| Antrum | 5(29.4%) | 13 (10.9%) | 0.085 | |
| Contour | | | 0.034^a | 0.747 |
| Round | 5 (29.4%) | 36(30.3%) | 0.944 | |
| Oval | 10 (58.8%) | 36(30.3%) | 0.020 | |
| Irregular | 2 (11.8%) | 47 (39.5%) | 0.026 | |
| Growth pattern | | | 0.232 ^a | |
| Endophytic | 4 (23.5%) | 57 (47.9%) | 0.059 | |
| Exophytic | 11 (64.7%) | 45 (37.8%) | 0.035 | |
| Mixed | 2 (11.8%) | 17 (14.3%) | 1.000 | |
| Peritumoral infiltration or fat-line of peritumor | | | <0.001 ^a | 0.001 |
| Yes | 6 (35.3%) | 3 (2.5%) | | |
| No | 11 (64.7%) | 116 (97.5%) | | |
| Necrosis | 1 (5.9%) | 41 (34.5%) | <0.001^a | 0.048 |
| Calcification | 0 (0%) | 23 (19.3%) | 0.048^a | 0.211 |
| Surface ulceration | 0 (0%) | 11 (9.2%) | 0.193 ^a | |
| Lymph node | 0 (0%) | 1 (0.8%) | 1.000 ^a | |
| Quantitative analysis | | | | |
| CT attenuation value | | | | |
| CTu (HU) | 40.55 ± 8.67 | 34.24 ± 7.19 | <0.001^b | 0.600 |
| CTa(HU) | 71.35 ± 19.49 | 54.57 ± 13.77 | 0.01^b | 0.901 |
| CTp(HU) | 95.09 ± 13.15 | 68.92 ± 17.87 | 0.003^b | 0.752 |
| Degree of enhancement | | | | |
| DEAP | 37.44 ± 15.70 | 20.37 ± 11.81 | <0.001^b | 0.047 |
| DEPP | 54.49 ± 17.69 | 34.26 ± 15.57 | <0.001^b | 0.762 |
| LD (mm) | 21.94 ± 11.81 | 35.26 ± 23.51 | 0.001^b | 0.097 |
| SD (mm) | 16.06 ± 6.07 | 28.55 ± 16.56 | <0.001^b | 0.069 |
| LD/SD | 1.329 ± 0.29 | 1.229 ± 0.21 | 0.07 | |

P values written in bold indicate a significant difference between the tumors. CTu/CTa/CTp = the CT attenuation value of unenhancement phase/arterial phase/portal venous phase; DEAP = the CT attenuation value of arterial phase—unenhanced phase; DEPP = the CT attenuation value of portal venous phase—unenhanced phase; LD = long diameter; SD = short diameter. Multivariate analysis was performed using logistic regression

^a χ^2 test

^b Independent t test

Discussion

Gastric ectopic pancreas (GEPs) is a pancreatic tissue which was found outside its normal localization and without any anatomical or vascular connection with pancreas [3, 11]. Although the majority of patients with GEPs were asymptomatic, a few patients may have clinical manifestations due to stimulation of hormones and enzymes secreted by the ectopic pancreas [11]. As the most common subepithelial lesion, GST accounts for

90% of gastric submucosal tumor [8, 9]. And it is difficult to differentiate GEPs from GST, so we compare the CT features of GEPs and GST to help us make the correct diagnosis.

Our study indicated that 0 (0%) of 17 cases of GEPs were located in gastric fundus and the majority of GEPs (64.7%) were located in gastric body, moreover, only 5 cases (29.4%) were located in gastric antrum. In contrast, 41 (34.4%) of 119 GST were located in gastric fundus and




Fig. 2 Patient 1, 50–60 years old, sex 1. Stromal tumor in gastric fundus (a–c). Axial CT scans (non-enhanced, arterial and portal phase) show an irregular mass with mixed growth pattern. Ulceration (*), calcification (arrow), necrosis (bend-arrow) are presented in the lesion and the mass shows mild to moderate heterogeneous enhancement (d–f). Histological and immunohistochemical images show that stromal tumor is positive for DOG1 (e) and CD117 (f)





Fig. 3 Patient 2, 40–50 years old, sex 1. Ectopic pancreas in gastric body (a–c). Axial CT scans (non-enhanced, arterial and portal phase) show an oval Exophytic mass in the gastric body and also the fat-line of peritumor (arrow). The lesion shows homogeneous enhancement and equal attenuation to the pancreas (d). The lesion was confirmed as ectopic pancreas pathologically

Table 3 Sensitivity and specificity of significant CT features for differentiating GEPs from GST

| CT features | Sensitivity | Specificity |
|---------------------------------------------------|-----------------|-----------------|
| Qualitative features | | |
| Location at the body and antrum | 94.1% (16/17) | 42% (50/119) |
| Round or oval | 88.2% (15/17) | 39.5% (47/119) |
| Peritumoral infiltration or fat-line of peritumor | 35.3% (6/17) | 97.5% (116/119) |
| Intralesional necrosis absence | 94.1% (16/17) | 34.5% (41/119) |
| Intralesional calcification absence | 100% (17/17) | 19.3% (23/119) |
| Quantitative features | | |
| LD (cut off: ≤ 25 mm) | 82.4% (14/17) | 79.0% (94/119) |
| SD (cut off: ≤ 22 mm) | 94.1% (16/17) | 59.7% (71/119) |
| CTu (cut off: ≥ 39.4 HU) | 64.7% (11/17) | 80.7% (96/119) |
| CTa (cut off: ≥ 39.4 HU) | 70.6% (12/17) | 88.2% (105/119) |
| CTp (cut off: ≥ 77.5 HU) | 100 and (17/17) | 76.5% (91/119) |
| DEAP (cut off: ≥ 32.2 HU) | 76.5% (13/17) | 84.0% (100/119) |
| DEPP (cut off: ≥ 42.5 HU) | 82.4% (14/17) | 79.0% (94/119) |


GEPs gastric ectopic pancreas, GST astrointestinal stromal tumor, LD long diameter, SD short diameter; CTu/CTa/CTp the CT attenuation value of unenhancement phase/arterial phase/portal venous phase, DEAP the CT attenuation value of arterial phase-unenhanced phase, DEPP the CT attenuation value of portal venous phase-unenhanced phase



56 (47.1%) cases were located in gastric body. However, the location of GEPs is inconsistent with the well-known fact that ectopic pancreases in upper gastrointestinal system are usually located in the gastric antrum [6–8, 12–14], and this may be resulted from small sample size of GEPs.

Moreover, 6 (35.3%) of 17 cases of GEPs in our study had the presence of peritumoral infiltration or fat-line

of peritumor, while only 3 (2.5%) of 119 cases of GST performed like that. Our result is similar to previous researches of Cho et al. [14] and Kim et al. [15] and consistent with typical endoscopic ultrasonography (EUS) characteristics, that is indistinct borders, lobulated margins, presence of anechoic duct-like structures, a mural growth pattern, and localization within two or more layers [16, 17]. The feature of peritumoral infiltration is



very closely correlated with the histological feature of a lobular structure of the acinous tissue at the margin [16]. Since most GEPs were exophytic growth pattern (64.7% [11/17]) and GEPs was not a true neoplasms but a hamartoma that flat pancreatic acinar formation and duct development histologically [6–8], so it is of high possibility for GEPs to have fat space between the tumor and serosal layer. As for GST, the main endoscopic finding of it is a nonspecific smooth bulge covered with normal mucosa, which is common to all subepithelial lesions [9], so the possibility for GST to have fat space between the tumor and serosal layer is extremely low. Furthermore, Mietinenn [18] reported the metastatic risk of GST increases according to the tumor size irrespectively of the mitotic count and the probability of malignancy was significantly increased when the tumor was larger than 5 cm in diameter. In our series, 86 cases of GST (72.3% [86/119]) were less than 5 cm in diameter and it is of low probability for GST in our study to invaded the serosal layer, which lead to the seldom presence of peritumoral infiltration.

In our series, 0 (0%) of the 17 cases of GEPs had the presence of calcification, surface ulceration and lymph node, just 1 (5.9%) case of GEPs had necrosis, our results were supported by the fact that GEPs was not a true neoplasm but a hamartoma of flat pancreatic acinar formation and duct development [6–8]. Our study also showed that the LD and SD of GEPs were shorter than GST, but the previous study [14] regarding the CT features of GEPs didn't regard it as a characteristic CT finding.

Our study demonstrated that the CT attenuation values of CTu, CTa and CTp of GEPs were significantly higher than that of GST. Besides, the degree of enhancement was much heavier for the GEPs than that of GST, both in the DEAP and DEPP. Furthermore, ROC analysis showed that the test efficiency of CTp in differentiating them was perfect (AUC = 0.9). The majority of GEPs appeared as homogeneously extramucosal masses with similar or higher attenuation to pancreas and this result may be attributable to the histologic similarity of GEPs to normal pancreatic tissue, especially acini. Microscopically, GEPs consist of pancreatic acini and ducts and rarely contain islet cells. If the GEPs was mainly composed of pancreatic

acini, the lesions would show greater enhancement and have a higher CT attenuation value in portal venous phase than the pancreas. On the contrary, if the GEPs consisted of predominantly ducts, the lesions would have lower CT attenuation values than pancreas and even the back muscles [14, 19, 20]. Our result showed that 16 of 17 GEPs mainly consisted of pancreatic acini and 1 of 17 GEPs contained many ducts and a few acini, and it is similar to the report of Yamagiwa et al. [20]. But for GST, as we know, GST had malignant potential and fast growth rate so as to tumor cell prone to degeneration, which undoubtedly decreased the degree of enhancement of GST [9, 21].

Our study has several limitations. Firstly, this was a retrospective study, the selection bias and the use of various CT scanners were inevitable. Secondly, only two types of gastric mesenchymal tumors were compared and other subepithelial lesions were ignored. Besides, in order to avoid the influence of size bias, we excluded larger GST because most of larger-sized gastric mesenchymal tumors can be diagnosed as GST eventually [22]. Thirdly, our results were based on clinical data obtained from an eastern country at a single institution, which could not reflect fully the image differences between the different races and regions of two groups.

In conclusion, gastric ectopic pancreas had characteristic CT findings that differ from gastric stromal tumor. When characteristic CT imaging findings are used in combination, ectopic pancreas can be differentiated from with a high degree of diagnostic accuracy.

Abbreviations

GEPs: Gastric ectopic pancreas; **GST:** Gastric stromal tumor; **CT:** Computed tomography; **CTu:** CT attenuation value of unenhancement phase; **CTa:** CT attenuation value of arterial phase; **CTp:** CT attenuation value of portal venous phase; **DEAP:** The CT attenuation value of arterial phase minus that of unenhanced phase; **DEPP:** The CT attenuation value of portal venous phase minus that of unenhanced phase; **LD:** Long diameter; **SD:** Short diameter; **ROC:** Receiver operating characteristic curve; **ROI:** Region of interest; **AUC:** Area under curve.

Acknowledgements

Not applicable.

Authors' contributions

Conceived and designed the experiments: JW. Analyzed the data: CL, JW performed the experiments: FY, WMZ, WQA, YYA, CZ, BLD, CLP. Wrote the paper: CL, JW. The authors read and approved the final manuscript.

Funding

This study is supported by the Medical Health Science and Technology Project of Zhejiang Province (Grant No. 2019RC028). The funder had no role in the design of the study and collection, analysis, and interpretation and in writing the manuscript.

Availability of data and materials

The data underlying this paper are available upon request to the corresponding author due to ethical restrictions.

Ethics approval and consent to participate

The study was approved by the institutional review board of TongDe Hospital of Zhejiang Province. Written informed consent was waived by the Institutional Review Board.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, #79 Qingchun Road, Hangzhou 310003, Zhejiang Province, P. R. China. ² Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou 310016, China. ³ Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou 310016, China. ⁴ Department of Radiology, TongDe Hospital of Zhejiang Province, No. 234, Gucui Road, Hangzhou 310012, Zhejiang Province, China.

Received: 12 May 2020 Accepted: 17 January 2021

Published online: 04 February 2021

References

- Low G, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. *Radiographics*. 2011;31(4):993–1015.
- Klob L. Pancreas accessorium. *Zeitschrift der Kaiserl. Königl. Gesellschaft der Aerzte zu Wien*, 1859; 15:732.
- Grendell JH, Ermak TH. Sleichenger & Fordtran's gastrointestinal and liver disease. 1998: Philadelphia, Pa: Saunders. 761–71.
- Emerson L, Layfield LJ, Rohr LR, Dayton MT. Adenocarcinoma arising in association with gastric heterotopic pancreas: a case report and review of the literature. *J Surg Oncol*. 2004;87(1):53–7.
- Papaziogias B, Koutelidakis I, Tsiaousis P, Panagiotopoulou K, Atmatzidis K. Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report. *Cases J*. 2008;1(1):249.
- Rooney DR. Aberrant pancreatic tissue in the stomach. *Radiology*. 1959;73:241–4.
- Kilman WJ, Berk RN. The spectrum of radiographic features of aberrant pancreatic rests involving the stomach. *Radiology*. 1977;123(2):291–6.
- Levine MS. Benign tumors of the stomach and duodenum. In: Gore RM, Levine MS, eds. *Textbook of gastrointestinal radiology*. 3rd ed. Philadelphia, Pa: Saunders. 3rd ed. 2008;593–617.
- Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. *World J Gastroenterol*. 2018;24(26):2806–17.
- Solito B, Santi S, Gambaccini D, Laino G, D'Imporzano S, Pallabazzer G, et al. Ectopic pancreas in the gastric antrum: a spectrum of imaging findings. *Pancreatol*. 2013;13(3):S44.
- Ormarsson OT, Gudmundsdottir I, Mårvik R. Diagnosis and treatment of gastric heterotopic pancreas. *World J Surg*. 2006;30(9):1682–9.
- Zinkiewicz K, Juśkiewicz W, Zgodziński W, Szumilo J, Cwik G, Furtak, et al. Ectopic pancreas: endoscopic, ultrasound and radiological features. *Folia Morphol (Warsz)* 2003; 62:(3) 205–9.
- Thoeni RF, Gedgaudas RK. Ectopic pancreas: usual and unusual features. *Gastrointest Radiol*. 1980;5(1):37–42.
- Kim JY, Lee JM, Kim KW, Park HS, Choi JY, Kim SH, et al. Ectopic pancreas: CT findings with emphasis on differentiation from small gastrointestinal stromal tumor and leiomyoma. *Radiology*. 2009;252(1):92–100.
- Cho JS, Shin KS, Kwon ST, Kim JW, Kang HK. Heterotopic pancreas in the stomach: CT findings. *Radiology*. 2000;217(1):139–44.
- Park SH, Kim GH, Park DY, Shin NR, Cheong JH, Moon JY, et al. Endosonographic findings of gastric ectopic pancreas: a single center experience. *J Gastroenterol Hepatol*. 2011;26(9):1411–46.
- Subasinghe D, Sivaganesh S, Perera N, Samarasekera DN. Gastric fundal heterotopic pancreas mimicking a gastrointestinal stromal tumour (GIST): a case report and a brief review. *BMC Res Notes*. 2016;9(1):185.

18. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with longterm follow-up. *Am J Surg Pathol*. 2005;29(1):52–68.
19. Park SH, Han JK, Choi BI, Kim M, Kim YI, Yeon KM, et al. Heterotopic pancreas of the stomach: CT findings correlated with pathologic findings in six patients. *Abdom Imaging*. 2000;25(2):119–23.
20. Yamagiwa H, Ishihara A, Sekoguchi T, Matsuzaki O. Heterotopic pancreas in surgically resected stomach. *Gastroenterol Jpn*. 1977;12(5):380–6.
21. Eisenberg BL, Pipas JM. Gastrointestinal stromal tumor-background, pathology, treatment. *Hematol Oncol Clin North Am*. 2012;26(6):1239–59.
22. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. *Radiographics*. 2003;23(2):283–304.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

